Davunetide intravenous

Drug Profile

Davunetide intravenous

Alternative Names: AL-208; Davunetide IV

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Allon Therapeutics
  • Class Antidementias; Eye disorder therapies; Neuropeptides; Neuroprotectants; Nootropics
  • Mechanism of Action Microtubule-associated protein inhibitors; Microtubule-associated protein modulators; Neuropeptide stimulants; Tau protein inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Dementia; Diabetic neuropathies; Eye disorders; Mild cognitive impairment; Stroke

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Dementia in USA (IV)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in Canada (IV)
  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top